What if your cancer didn’t begin as bad luck in your DNA — but was fueled by hidden infections your doctors never tested for?

In this episode of Outsmart Cancer, Dr. Dino Prato explains how chronic, undiagnosed infections can weaken the immune system, drive inflammation, disrupt tumor-suppressor pathways, and make cancer more aggressive and resistant to treatment.

While global estimates suggest about 13% of cancers are linked to infections, Dr. Prato’s clinical experience over more than 25 years shows the number may be far higher — largely because most patients are never thoroughly tested. Viruses, bacteria, parasites, mold toxins, and tick-borne infections can persist silently in the body, suppressing immunity long before cancer develops.

Dr. Prato breaks down the three primary ways infections contribute to cancer: direct oncogenic interference with tumor-suppressor genes like p53, genomic instability caused by viral integration, and chronic inflammation that fuels tumor growth and immune exhaustion. He also explains how infections disrupt mitochondrial signaling, impair natural killer cell function, and interfere with modern treatments — including immunotherapy.

This episode highlights why eliminating infections and restoring immune function must be part of precision oncology. Without addressing these hidden drivers, even the most advanced cancer therapies may fail to reach their full effectiveness.

🎯 What You’ll Learn in This Episode:

• Why infections are an overlooked contributor to cancer
• How viruses like HPV, EBV, and hepatitis affect tumor-suppressor genes
• The role of chronic inflammation and immune exhaustion
• Why infections increase treatment resistance and immune evasion
• How mitochondrial dysfunction impacts cancer immunity
• Why deep infectious disease testing is essential
• How eliminating infections can improve treatment response
  
  

📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: www.envita.com
📞 Speak with a care coordinator: 866-830-4576

“Cancer treatment works best when the immune system is no longer under attack.”

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at:

https://www.scirp.org/journal/paperinformation?paperid=132493

If you’ve been told you have a KRAS mutation — or another so-called “undruggable” cancer gene — you may have been placed on a specialty inhibitor designed to slow the disease. And these drugs can be helpful. But there’s a critical truth most patients are never told:

Most targeted cancer drugs are cytostatic, not cytotoxic.
They slow cancer down — they don’t eliminate it.

In this episode of Outsmart Cancer, Dr. Dino Prato explains why drugs targeting KRAS, BRAF, EGFR, MET, HER2, and similar pathways often create a temporary “honeymoon period.” Like unplugging a Christmas tree, the tumors dim — but once the drug stops working, the cancer lights back up.

The key question becomes: What are you doing with the time these drugs buy you?

Dr. Prato walks through how precision oncology uses that window to activate the immune system. By combining full DNA sequencing, RNA transcriptomics, immune spatial biology, and deep pathway mapping, doctors can identify thousands of targets — not just one mutation. This allows precision combinations, off-label strategies, phytotherapeutics, and direct-to-tumor immunotherapy delivery to expose cancer antigens, release DAMPS, and train natural killer and dendritic cells to eliminate disease system-wide.

Instead of waiting for resistance, this approach turns cytostatic slowdown into cytotoxic immune control, even in patients labeled MSS or “not candidates” for standard immunotherapy.

🎯 What You’ll Learn in This Episode:
• Why KRAS and similar inhibitors slow cancer but rarely eliminate it
• The difference between cytostatic and cytotoxic cancer treatment
• Why specialty drugs create a critical treatment window
• How RNA transcriptomics reveals escape pathways beyond DNA mutations
• Why immune spatial biology is essential for durable response
• How direct-to-tumor delivery protects immunity and increases effectiveness
• Why PD-1 inhibitors alone are rarely enough
• The right questions to ask when your targeted drug stops working

📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: www.envita.com
📞 Speak with a care coordinator: 866-830-4576

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at:

https://www.scirp.org/journal/paperinformation?paperid=132493

Something most cancer patients are never told:
the radiation plan you receive is often influenced by the machine a hospital owns, not by what’s best for your cancer biology.

Dr. Dino Prato breaks down the radiation wars — and introduces a disruptive technology that may change oncology entirely: ultrasound-based tumor destruction. Data shows that 40–50% of radiation therapy is palliative, meaning it’s designed to slow disease or reduce symptoms rather than eliminate cancer. The real question becomes: what are we doing during that time?

Dr. Prato explains why radiation has long been an adjuvant tool, how hospital economics and reimbursement drive its overuse, and why newer technologies often struggle to gain adoption. He then introduces histotripsy and sonodynamic therapy, which use focused sound waves to “melt” tumors without radiation. This process creates a tumor lysate rich in antigens, neoantigens, and DAMPS — powerful immune signals that can be repurposed into systemic immunotherapy.

Using precision oncology principles — DNA sequencing, RNA transcriptomics, immune profiling, spatial biology, and AI-guided analysis — this lysate can be combined with immunotherapy, phytotherapeutic adjuvants, and nanoparticle delivery to stimulate whole-body immune response, not just local tumor control.

This episode explores why ultrasound-based approaches may replace large portions of radiation oncology in the future, why adoption is slow, and how immune-centric precision care shifts cancer treatment from palliative delay to strategic immune activation.

🎯 What You’ll Learn in This Episode:
• Why 40–50% of radiation therapy is palliative
• How hospital ownership influences radiation decisions
• The difference between radiation destruction and immune training
• What histotripsy and sonodynamic therapy are
• How tumor lysate becomes immunotherapy
• Why ultrasound avoids many radiation side effects
• How precision oncology integrates sound, data, and immunity
• Why disruptive cancer technology takes years to reach patients

📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: www.envita.com
📞 Speak with a care coordinator: 866-830-4576

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at:

https://www.scirp.org/journal/paperinformation?paperid=132493

Why do some cancer patients relapse even after surgery, chemo, and radiation — while others recover long-term?

In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, explains the missing link most oncologists never talk about: DAMPS — Damage Associated Molecular Patterns. These are the danger signals cancer cells release when they die, and they determine whether your immune system wakes up… or whether the cancer becomes more resistant.

You’ll learn why too much chemotherapy or radiation can release uncontrolled DAMPS, triggering inflammation, mutations, and relapse — especially in late-stage disease. And you’ll discover how microdosed, genetically targeted chemotherapy, combined with immune profiling and spatial biology, activates DAMPS in the right way to train your immune system for long-term control.

Dr. Prato walks through how adaptive monitoring (CTCs, ctDNA, methylation), nutritional changes, sleep, inflammation control, phytotherapy, and cellular biologics all work together to keep immune signals tuned and prevent relapse.

🎯 What You’ll Learn in This Episode:
• What DAMPS are — and why they determine relapse or recovery
• How high-dose chemo/radiation can trigger resistance and mutations
• Why microdosed, targeted chemotherapy activates the “right” immune signals
• How NK cells, dendritic cells & immune profiling enhance DAMPS response
• How sleep, diet, inflammation markers, and stress impact immune signaling
• Why liquid biopsies (CTCs, ctDNA, methylation) reveal relapse early
• How personalized dosing prevents overactivation and immune collapse
• Why the future of cancer care is immune-centric precision oncology

📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: www.envita.com
📞 Speak to a care coordinator: 866-830-4576

“When you align treatment with immune signaling, you stop fighting cancer — you teach your body to win.”

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at:

https://www.scirp.org/journal/paperinformation?paperid=132493

What if the best cancer treatment for you can’t be mass-produced? What if the drug, dose, pathway targets, and delivery route all have to be custom-designed from the ground up — not because it's luxurious, but because it’s necessary?

In this episode of Outsmart Cancer, Dr. Dino Prato explains why true precision oncology is fundamentally different from standard cancer care. Inspired by the St. Jude model for rare pediatric cancers, Dr. Prato reveals why adults with heterogeneous tumors also need custom-built therapies created from DNA sequencing, RNA transcriptomics, immune spatial biology, and real-time monitoring.

Instead of relying on one-size-fits-all guidelines and limited FDA-approved drugs, N-of-1 oncology builds a personalized playbook using on-label, off-label, repurposed drugs, phytotherapeutics, and cellular biologics — all designed around each patient’s unique molecular drivers. This ecosystem includes custom drug compounding, microdosed combination therapy, direct-to-tumor delivery, and immune rebuilding through NK and dendritic cell biologics.

🎯 What You’ll Learn in This Episode:
• Why standard care cannot treat today’s heterogeneous, complex cancers
• How St. Jude’s precision model inspired Envita’s N-of-1 adult ecosystem
• How DNA, RNA, and spatial biology testing reveal thousands of unique targets
• Why custom-built drugs and phytotherapeutics outperform off-the-shelf options
• How cellular biologics (NK & dendritic cells) rebuild immune killing
• Why direct-to-tumor delivery beats systemic chemotherapy for many patients
• What real-time monitoring (CTCs, methylation, ctDNA) reveals long before imaging

📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: www.envita.com
📞 Speak to a care coordinator: 866-830-4576

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at:

https://www.scirp.org/journal/paperinformation?paperid=132493

Your body is a city — and your immune system is its army. Every day, it stops thousands of threats without you ever knowing. But when cancer learns to hide behind fake ID badges, jam the “radio signals,” or build stromal barriers, the immune system can lose its ability to see the enemy.

In this powerful episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, uses storytelling to explain exactly how the immune system works — and how cancer escapes detection. From neutrophils and macrophages to dendritic detectives, natural killer cells, and T-cell commanders, you’ll discover what makes your inner army strong… and what causes it to break down.

Dr. Prato also shows how deep immune profiling, DNA/RNA sequencing, and spatial biology help rebuild the immune system through targeted, immune-centric cancer care. By restoring the body’s natural defenses, patients can turn “cold tumors hot” and achieve more durable, long-term control.

🎯 What You’ll Learn in This Episode:
• How NK cells, T cells, dendritic cells, and macrophages really work
• Why cancer hides using fake ID, checkpoints, and stromal barriers
• How toxins, infections, and heavy metals weaken the immune system
• Why PD-1 inhibitors often fail without full immune-system repair
• The 8-step immune kill loop — and how cancer breaks it
• How deep mapping restores immune visibility and targeting

📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: www.envita.com
📞 Speak to a care coordinator: 866-830-4576

“Your immune system isn’t weak — it’s misdirected. Precision helps it see clearly again.”

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at:

https://www.scirp.org/journal/paperinformation?paperid=132493

What if the goal of cancer treatment wasn’t more drug — but smarter delivery?

In this episode of Outsmart Cancer, Dr. Dino Prato explains how peptides and metabolic primers can dramatically improve the effectiveness of precision oncology when used correctly. Drawing from more than 25 years of clinical experience, Dr. Prato walks through the evolution from early insulin potentiation therapy (IPT) to today’s genetically targeted fractionated chemotherapy (GTFC) — a data-driven, immune-centric approach built on deep molecular mapping.

You’ll learn why insulin is not a treatment on its own, but a primer that can temporarily increase tumor uptake of microdosed chemotherapy — only when specific biomarkers are present. Dr. Prato explains how most chemotherapy misses the tumor entirely, and how metabolic primers like insulin, fasting windows, oxygenation, and redox modulation can shift that equation while protecting the immune system.

This episode breaks down how DNA sequencing, RNA transcriptomics, immune profiling, and spatial biology are used to select the right drugs first — and only then decide whether a primer like insulin makes sense. When combined correctly, this strategy promotes immunogenic cell death (DAMPS), trains dendritic cells and NK cells, and supports long-term immune control rather than short-term tumor suppression.

This is not alternative therapy. It’s precision delivery, immune intelligence, and metabolic strategy working together.

🎯 What You’ll Learn in This Episode:
• Why insulin is a peptide primer — not a cancer treatment
• How early insulin potentiation evolved into modern GTFC
• Why most chemotherapy never reaches the tumor
• How fasting and metabolic preparation improve drug tolerance
• What DAMPS are and why immune signaling determines long-term outcomes
• When insulin, oxygen, or inflammatory primers are appropriate — and when they’re not
• Why deep DNA, RNA, and immune mapping must come first
• How microdosed therapy strengthens immunity instead of destroying it

📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: www.envita.com
📞 Speak with a care coordinator: 866-830-4576

“Precision isn’t about adding more — it’s about delivering smarter.”

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at:

https://www.scirp.org/journal/paperinformation?paperid=132493

What is the best treatment for advanced melanoma — and why do some therapies fail while others succeed?

In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, breaks down the future of melanoma care: deep mapping and immune-centered precision oncology. Using DNA, RNA, and spatial biology, Dr. Prato explains how mapping every pathway — not just BRAF mutations — gives doctors a full picture of the tumor’s environment, revealing why PD-1 inhibitors, BRAF/MEK drugs, and other standard therapies work for only a small group of patients.

The key to melanoma, he says, lies in natural killer (NK) cells. These immune cells, trained through AAIT (Autologous Adoptive Immunotherapy), can cross the blood-brain barrier and destroy tumor cells without the side effects of high-dose systemic drugs. By combining deep mapping, immune retraining, and microdosed precision therapies, Envita helps patients move from reactionary care to immune-guided treatment.

🎯 What You’ll Learn in This Episode:
• Why most standard melanoma treatments only help a small percentage of patients
• How DNA, RNA, and spatial biology mapping reveal hidden resistance pathways
• The difference between TIL therapy and AAIT (Autoglutid Adaptive Immunotherapy)
• How NK and dendritic cells are trained using DAMPs to target melanoma cells
• Why changing the tumor microenvironment is critical for immune response
• How AAIT avoids cytokine storms and side effects seen in other therapies

📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: www.envita.com

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at:

https://www.scirp.org/journal/paperinformation?paperid=132493